These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1194 related articles for article (PubMed ID: 25440090)

  • 1. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
    Ohaegbulam KC; Assal A; Lazar-Molnar E; Yao Y; Zang X
    Trends Mol Med; 2015 Jan; 21(1):24-33. PubMed ID: 25440090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.
    Gandini S; Massi D; Mandalà M
    Crit Rev Oncol Hematol; 2016 Apr; 100():88-98. PubMed ID: 26895815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
    Liu B; Song Y; Liu D
    J Hematol Oncol; 2017 Dec; 10(1):174. PubMed ID: 29195503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
    Sznol M; Chen L
    Clin Cancer Res; 2013 Mar; 19(5):1021-34. PubMed ID: 23460533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
    Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.
    Córdova-Bahena L; Velasco-Velázquez MA
    Rev Invest Clin; 2020 Oct; 73(1):008-016. PubMed ID: 33079077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and PD-L1 antibodies for melanoma.
    Tsai KK; Zarzoso I; Daud AI
    Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
    Liu M; Sun Q; Wei F; Ren X
    Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.
    Zhulai G; Oleinik E
    Scand J Immunol; 2022 Mar; 95(3):e13129. PubMed ID: 34936125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 in disease.
    Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
    Hirsch L; Zitvogel L; Eggermont A; Marabelle A
    Br J Cancer; 2019 Jan; 120(1):3-5. PubMed ID: 30413824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 60.